These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 24218541)
1. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. Dowty ME; Jesson MI; Ghosh S; Lee J; Meyer DM; Krishnaswami S; Kishore N J Pharmacol Exp Ther; 2014 Jan; 348(1):165-73. PubMed ID: 24218541 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Tanaka Y; Maeshima K; Yamaoka K Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142 [TBL] [Abstract][Full Text] [Related]
4. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. Mohamed MF; Beck D; Camp HS; Othman AA J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433 [TBL] [Abstract][Full Text] [Related]
5. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. Craiglow BG; King BA JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994 [TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976 [TBL] [Abstract][Full Text] [Related]
7. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. Tanaka Y J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731 [TBL] [Abstract][Full Text] [Related]
8. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069 [TBL] [Abstract][Full Text] [Related]
9. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis. Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420 [TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636 [TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Bannwarth B; Kostine M; Poursac N Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265 [TBL] [Abstract][Full Text] [Related]
13. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Tanaka Y; Yamaoka K Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593 [TBL] [Abstract][Full Text] [Related]
14. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347 [TBL] [Abstract][Full Text] [Related]
16. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis. Gupta AK; Cernea M; Lynde CW Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404 [TBL] [Abstract][Full Text] [Related]